Daiichi Sankyo Korea Co., Ltd. clinical trials
A country office of Daiichi Sankyo
The registry lists 1 studies whose lead sponsor is Daiichi Sankyo Korea Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 24, 2018.
Registry sponsor names on this page
- Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company1 study
Something wrong with this grouping? Tell us on the Daiichi Sankyo page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Daiichi Sankyo studies →
- Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination TherapyCompletedNCT01838850Phase 3
Sponsor listed in the registry: Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company